Merdury Biopharmaceutical

Merdury Biopharmaceutical Current Liabilities

The Current Liabilities of Merdury Biopharmaceutical (6932.TWO) as of Oct 18, 2026 is 438,000.00 TWD. In the previous year, Current Liabilities was 11.44 M TWD — a change of -96.17% (lower).

Current Liabilities

438,000.00TWD

YoY

-96.17%

Last updated:

Current Liabilities of Merdury Biopharmaceutical is 2025 438,000.00 TWD. Current Liabilities of Merdury Biopharmaceutical was 2024 11.44 M TWD. It decreases by -96.17% lower compared to the previous year.

The Merdury Biopharmaceutical Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
162,000.00 TWD
Jan 1, 2020
312,000.00 TWD
Jan 1, 2021
3.15 M TWD
Jan 1, 2022
12.89 M TWD
Jan 1, 2023
13.80 M TWD
Jan 1, 2024
11.44 M TWD
Jan 1, 2025
438,000.00 TWD
The Merdury Biopharmaceutical Current Liabilities history
YEARCurrent LiabilitiesYoY
438,000.00TWD-96.17%
11.44 MTWD-17.08%
13.80 MTWD+7.04%
12.89 MTWD+308.95%
3.15 MTWD+910.26%
312,000.00TWD+92.59%
162,000.00TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Merdury Biopharmaceutical Stock analysis

What does Merdury Biopharmaceutical do? Merdury Biopharmaceutical Corp is a pharmaceutical company based in Taipei, Taiwan, operating within the Health Care sector. The company has a small workforce of 13 employees and went public on December 23, 2022, with its ticker listed as 6932.TWO. Merdury Biopharmaceutical Corp focuses on developing drugs that address unmet medical needs, difficult generic drugs, and second-class new drugs. The company utilizes a self-developed drug development platform called StackDose, which enables the creation of tablets with controlled dissolution properties, allowing for either immediate or sustained drug release. This technology supports the development of products such as Sildenafil, Metformin, Tadalafil, Zolpidem, angina treatments, migraine medications, and multi-ingredient antihypertensive drugs. These products are primarily marketed and sold in Taiwan and the United States. The company's website is https://merdury.com, providing further information about its operations and offerings. Merdury Biopharmaceutical Corp operates as a publicly traded entity with a focus on innovative pharmaceutical solutions within the Taiwanese and U.S. markets. Merdury Biopharmaceutical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Merdury Biopharmaceutical stock

Current Liabilities of Merdury Biopharmaceutical is 438,000.00 TWD in 2025.

Current Liabilities of Merdury Biopharmaceutical changed from 11.44 M TWD to 438,000.00 TWD, representing a -96.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Merdury Biopharmaceutical since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Merdury Biopharmaceutical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Merdury Biopharmaceutical

All Key Metrics — Merdury Biopharmaceutical